LSI USA 2026: March 16–20

Versono Medical will attend the LSI USA conference in California from March 16 to 20. LSI brings together MedTech innovators, investors and strategic partners to discuss emerging technologies and investment opportunities in healthcare.
Versono Medical will be represented by CTO Hugh O’Donoghue, CFO Padraic Clarke and CEO Finbar Dolan. During the conference, Finbar Dolan will present the company’s Prosonic System and discuss one of the key challenges in treating chronic total occlusions (CTOs).

In complex peripheral artery disease, particularly in below-the-knee and below-the-ankle vessels, crossing the occlusion is often the barrier to treatment. If the lesion cannot be crossed, treatment cannot proceed.
Many patients with chronic limb-threatening ischemia (CLTI) fall into this category and face a high risk of amputation when revascularisation is not possible.

The presentation will explore this “no cross, no treatment” challenge and how the Prosonic System is designed to enable intraluminal crossing through complex occlusions, opening a pathway to revascularisation for patients who may otherwise have limited treatment options.

If you would like to arrange a meeting with the Versono team during LSI USA, please contact Alison Kavanagh at [email protected] .